Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
1don MSN
Why Revolution Medicines (RVMD) still looks like a prime takeover target after daraxonrasib data
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the 10 potential takeover targets with strong price momentum. The appeal ...
The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a ...
A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...
By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...
In a trial, metastatic pancreatic cancer patients on the medicine lived twice as long as those on chemotherapy.
Revolution Medicines (RVMD) priced a public offering of 10.56M shares at $142 each, raising about $1.5B, along with $500M of convertible senior notes due 2033. Both offerings were upsized from earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results